Efficacy and safety of cisplatin for the management of adult patients with oral cancer
A protocol for systematic review
Yao Feng, MMa,∗, Dian-song Yang, MMb, Hai-bo Tang, MBb, Yuan-sheng Ding, MMc, Xiao-guang Li, MMc

Abstract
Background: Cisplatin is often used for the treatment of oral cancer (OC). However, there are inconsistent results. Thus, this study plans to systematically assess the clinical efficacy and safety of cisplatin for adult patients with OC.

Methods: We will search for PUBMED, EMBASE, Cochrane Library, AMED, Cumulative Index to Nursing and Allied Health Literature, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure. All of them will be searched from the construction of each database up to the present with no restrictions of language and publication status. The data analysis will be conducted using RevMan 5.3 software to assess the efficacy and safety of cisplatin for adult patients with OC.

Results: This study will summarize the most recent high-quality evidence and will provide helpful information about the efficacy and safety of cisplatin for adult patients with OC.

Conclusion: The findings of this study will provide convinced evidence of cisplatin for adult patients with OC, and provide recommendations for clinical practice.

Systematic review registration: PROSPERO CRD42019156658.

Abbreviations: CIs = confidence intervals, OC = oral cancer, RCTs = randomized controlled trials.

Keywords: cisplatin, efficacy, oral cancer, safety

1. Introduction
Oral cancer (OC) is one of the most common cancers worldwide, and has a 5-year survival rate of around 50%.11–14 It has been reported about 354,864 new cases of OC were identified, and 177,384 people died from OC globally in 2018.15 Although new patients have been diagnosed increasingly, most patients are still diagnosed at late and advanced stages at the initial diagnosis.6–9 Due to its anatomic location, patients with such disorder often experience very poor quality of life, impairment of most vital functions, as well as their appearances.10–12 Thus, it is very urgent to treat such condition timely and effectively.

Cisplatin has been reported to treat a variety of cancers effectively, especially for OC.13–16 However, there is still no systematic evidence of cisplatin for the treatment of adult patients with OC.17–21 Therefore, this study will assess the efficacy and safety of cisplatin for the treatment of adult patients with OC systematically.

2. Methods
2.1. Inclusion criteria
2.1.1. Types of studies. Any randomized controlled trials (RCTs) using cisplatin to treat adult patients with OC will be included, regardless of blinding, and allocation concealment.

2.1.2. Types of patients. This study will include adult patients (aged more than 18 years old) who were diagnosed as OC without limitations of gender, race, and duration of disease.

2.1.3. Types of interventions. The patients in the experimental group received cisplatin treatment, regardless its forms and dosage. The patients in the control group received any routine treatments, such as radiation therapy, surgery, and any others, except cisplatin.

2.1.4. Type of outcome measurements. The primary outcomes are overall survival and pathological complete response. The secondary outcomes are recurrence-free survival; disease-free survival; quality of life, as measured by 36-Item Short Form Health Survey or any related tools; and toxicities.

2.2. Data sources and search strategy
2.2.1. Electronic searches. We will carry out comprehensive search from the construction of each database up to the present with no restrictions of language and publication status from following electronic databases: PUBMED, EMBASE, Cochrane Library, AMED, Cumulative Index to Nursing and Allied Health...
Literature, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure. The search strategy for PUBMED is showed in Table 1. We also plan to build similar search strategies for other electronic databases.

2.2.2. Other resources. We will also check dissertations, ongoing trials, and reference lists of identified studies to avoid losing any potential studies.

2.3. Data collection and analysis

2.3.1. Study selection. All identified papers will be checked through scanning their titles and abstracts by 2 independent authors. Then, we will exclude all irrelevant studies. The rest literatures will be read by full texts to further judge if they meet all inclusion criteria. Any excluded studies will be recorded with clear reasons. Any divergences between 2 authors will be settled down by a third author through discussion. The study selection will be presented in the flowchart.

2.3.2. Data collection process. Two authors will independently carry out data collection using pre-designed data extraction form. It consists of study characteristics (such as first author name, publication date, title, country, et al), patient characteristics (such as race, age, gender, inclusion criteria, et al), study methods (such as sample size calculation, methods of randomization, blind, et al), study treatments (such as intervention types, frequency, dosage, et al), all outcomes, safety, and other relevant information. When there is any missing or insufficient information, we will contact original authors by email to require them. Any divergences between 2 authors will be resolved by a third author via discussion.

2.4. Risk of bias assessment

Two authors will independently evaluate risk of bias of each included trial using Cochrane risk of bias tool according to the specific Guidelines of Cochrane Handbook for Systematic Reviews of Interventions. It has 7 detailed items, and each one is further assessed as “low risk of bias”, “unclear risk of bias”, and “high risk of bias”. Any disagreements will be solved by another author via discussion.

2.5. Assessment of heterogeneity

We will estimate heterogeneity among eligible studies using I² statistic test. The value of $I^2 \leq 50\%$ refers low heterogeneity, while the value of $I^2 > 50\%$ exerts significant heterogeneity.

2.6. Subgroup analysis

If there are sufficient studies for data pooling with substantial heterogeneity, we will perform subgroup analysis to explore reasons for such obvious heterogeneity according to the different risk of bias, treatments, comparators, and outcome measurements.

2.7. Sensitivity analysis

We will consider conducting sensitivity analysis to check stability of pooled results by eliminating low quality studies.

2.8. Reporting bias

If at least 10 included RCTs are entered in this study, we will perform funnel plots to check any potential reporting bias.\textsuperscript{[22]}

2.9. Statistical analysis

RevMan 5.3 software will be used to carry out data analysis. For continuous data, mean difference or standardized mean difference and 95% confidence intervals (CIs) will be expressed. For dichotomous data, risk ratio and 95% CIs will be calculated. Heterogeneity across included trials will be identified using $I^2$ statistic. $I^2 \leq 50\%$ indicates included studies have homogeneity, and a fixed-effects model will be selected. $I^2 > 50\%$ means eligible studies have significant heterogeneity, and a random-effects model will be adopted. If there is homogeneity among more than 2 studies with similar treatments, controls, and outcomes, we will perform meta-analysis. If there is substantial heterogeneity, subgroup analysis will be operated. If there is still obvious heterogeneity after subgroup analysis, outcome data are not available for quantitative analysis, and we will report study results by qualitative description.

2.10. Ethics and dissemination

This study will not need research ethic, because we will use individual patient data. It is expected to be published on a peer-reviewed journal.

3. Discussion

OC is a devastating disease, which can result in highly morbidity and mortality in both males and females. Although promising advancements in its management approaches available, the overall efficacy is still not satisfied. Fortunately, previous studies have reported that cisplatin can benefit adult patients with OC. However, there is still not systematic review to address it. Therefore, this study will assess the efficacy and safety of cisplatin for the treatment of adult patients with OC. The results of this
Author contributions

Conceptualization: Yao Feng, Dian-song Yang, Hai-bo Tang, Yuan-sheng Ding, Xiao-guang Li.

Data curation: Dian-song Yang, Hai-bo Tang, Yuan-sheng Ding, Xiao-guang Li.

Formal analysis: Yao Feng, Hai-bo Tang, Yuan-sheng Ding.

Funding acquisition: Yao Feng.

Investigation: Yao Feng, Dian-song Yang, Xiao-guang Li.

Methodology: Dian-song Yang, Hai-bo Tang, Yuan-sheng Ding, Xiao-guang Li.

Project administration: Yao Feng, Dian-song Yang.

Resources: Hai-bo Tang, Yuan-sheng Ding, Xiao-guang Li.

Software: Dian-song Yang, Hai-bo Tang, Yuan-sheng Ding, Xiao-guang Li.

Supervision: Yao Feng.

Validation: Yao Feng, Dian-song Yang, Hai-bo Tang, Yuan-sheng Ding, Xiao-guang Li.

Visualization: Yao Feng, Hai-bo Tang, Yuan-sheng Ding, Xiao-guang Li.

Writing – original draft: Yao Feng, Yuan-sheng Ding, Xiao-guang Li.

Writing – review & editing: Yao Feng, Dian-song Yang, Hai-bo Tang, Yuan-sheng Ding, Xiao-guang Li.

References

[1] Madera Anaya MV, Franco JV, Merchán-Galvis ÁM, et al. Quality assessment of clinical practice guidelines on treatments for oral cancer. Cancer Treat Rev 2018;65:47–53.

[2] Gupta N, Gupta R, Acharya AK, et al. Changing trends in oral cancer - a global scenario. Nepal J Epidemiol 2016;8:613–9.

[3] Rhodus NL. Oral cancer update: 2017. Northwest Dent 2017;96:21–3.

[4] Calixto G, Bernegossi J, Fonseca-Santos B, et al. Nanotechnology-based drug delivery systems for treatment of oral cancer: a review. Int J Nanomedicine 2014;9:3719–35.

[5] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.

[6] Kao SY, Mao L, Jian XC, et al. Expert consensus on the detection and screening of oral cancer and precancer. Chin J Dent Res 2015;18:79–83.

[7] Mehrotra R, Gupta DK. Exciting new advances in oral cancer diagnosis: avenues to early detection. Head Neck Oncol 2011;3:33.

[8] Gumer P, Epstein JB. Late stage diagnosis of oral cancer: components and possible solutions. Oral Oncol 2014;50:1131–6.

[9] Chen XJ, Zhang XQ, Liu Q, et al. Nanotechnology: a promising method for oral cancer detection and diagnosis. J Nanobiotechnol 2018;16:52.

[10] Rivera C. Essentials of oral cancer. Int J Clin Exp Pathol 2015;8:11884–94.

[11] Prince VM, Papagerakis S, Prince ME. Oral cancer and cancer stem cells: relevance to oral cancer risk factors, premalignant lesions, and treatment. Curr Oral Heal Rep 2016;3:65–73.

[12] Paton DW, Ali A, Davies R, et al. Oral rehabilitation and quality of life following the treatment of oral cancer. Dent Update 1994;21:231–4.

[13] Sato K, Hayashi Y, Watanabe K, et al. Concurrent chemoradiotherapy with intravenous cisplatin and docetaxel for advanced oral cancer. Nagoya J Med Sci 2019;81:807–14.

[14] Chiang TE, Ho CJ, Lin CS, et al. Complete remission in very advanced oral cancer by docetaxel, cisplatin, 5-fluorouracil based induction chemotherapy followed by concurrent chemotherapy. J Dent Sci 2018;13:82–4.

[15] Chen CF, Lu CC, Chiang JH, et al. Synergistic inhibitory effects of cetuximab and curcumin on human cisplatin-resistant oral cancer CAR cells through intrinsic apoptotic process. Oncol Lett 2018;16:6323–30.

[16] Tang X, Hu YJ, Ju WT, et al. Elevated growth differentiating factor 15 expression predicts long-term benefit of docetaxel, cisplatin and 5-fluorouracil induction chemotherapy in patients with oral cancer. Oncol Lett 2018;15:8118–24.

[17] Rohde S, Kovács AF, Turowski B, et al. Intra-arterial high-dose chemotherapy with cisplatin as part of a palliative treatment concept in oral cancer. AJNR Am J Neuroradiol 2005;26:1804–9.

[18] Kovács AF. Chemoembolization using cisplatin crystals as neoadjuvant treatment of oral cancer. Cancer Biother Radiopharm 2005;20:267–79.

[19] Tegeder I, Bräutigam L, Seegel M, et al. Cisplatin tumor concentrations after intra-arterial cisplatin infusion or embolization in patients with oral cancer. Clin Pharmacol Ther 2003;73:417–26.

[20] Andreiadis C, Vahsetanos K, Sidiras T, et al. 5-Fluorouracil and cisplatin in the treatment of advanced oral cancer. Oral Oncol 2003;39:380–5.

[21] Wada T, Harada M, Morita N, et al. Chemotherapy administered using two-route infusion of cisplatin and sodium thiosulfate and intravenous infusion of vinblastine and peplomycin in patients with oral cancer. Clin Ther 1995;17:280–9.

[22] Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005;58:882–93.